Mobility Performance in Daily Activities Among Children Wearing Spectacle Lenses
NCT ID: NCT07229352
Last Updated: 2025-12-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
20 participants
INTERVENTIONAL
2026-01-31
2026-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SightGlass Vision Test Arm 1
Single vision, impact-resistant spectacle lenses
Novel spectacle lens design
Use of lenses may reduce the rate of progression of juvenile myopia
SightGlass Vision Test Arm 2
Single vision, impact-resistant spectacle lenses
Spectacle lenses
Use of lenses may reduce the rate of progression of juvenile myopia
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Novel spectacle lens design
Use of lenses may reduce the rate of progression of juvenile myopia
Spectacle lenses
Use of lenses may reduce the rate of progression of juvenile myopia
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Are between the ages of 6 and 12 years of age (inclusive) at the time of informed consent/assent.
* Can achieve a corrected visual acuity of 20/20 best-corrected (or equivalent logMAR).
* Have undergone a self-reported oculo-visual examination within the past two years.
* Have no active ocular disease.
* Are willing and able to adhere to instructions, study procedures, and maintain the appointment schedule.
* Have not previously worn or participated in myopia control contact lenses for more than one month and are not currently undergoing any form of myopia control treatment.
* The subject's parent(s) or legal guardian(s) must read, understand, and sign the Statement of Informed Consent and receive a fully executed copy of the form.
Exclusion Criteria
* Have any systemic disease that affects ocular health.
* Are currently using or have used, within the past 7 days, any systemic or topical medications that may impact ocular health.
* Are currently using or have used any topical ophthalmic agents with anti-muscarinic properties within 7 days prior to enrollment or at any point during the study. This includes, but is not limited to, atropine, scopolamine, pirenzepine, tropicamide, cyclopentolate, and homatropine.
* Have used any oral agents with anti-muscarinic properties for a chronic period (2 months or more) or short-term (within 7 days prior to enrollment). This includes, but is not limited to, gastrointestinal anti-spasmodic medications containing atropine, hyoscyamine, and dicyclomine.
* Have known developmental delays.
* Have participated in another clinical study in the last 7 days
6 Years
12 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
SightGlass Vision, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Midwestern University Arizona College of Optometry
Glendale, Arizona, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Javier Gantes-Nunez
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CPRO-2507-001
Identifier Type: -
Identifier Source: org_study_id